Kornimate/medical-research-clean huggingface dataset:
the influence of meibomian gland expression on corneal aberrations in mgd patients

Conditions: Meibomian Gland Dysfunction

Summary: to evaluate the influence of corneal-aberrations before and after the meibomian gland thermal massage treatment.

62 mgd patients treated with meibomian gland thermal massage once a week for 3 to 4 weeks were recruited.the ocular surface disease index questionnaire; tear film assessment encompassing tear meniscus height and non-invasive keratograph breakup time ; meibography score,corneal fluorescein staining; the schirmer i test ; expressible meibomian gland, and quality ,anterior and total corneal aberrations were evaluated before and after treatment.

Eligibility criteria:
inclusion criteria: * tear break-up time (but) ≤10 seconds or schirmer i test (sit) ≤10 mm, the presence of dry eye symptoms, and fluorescein staining (fl) score \<3 points and at least one lid margin abnormality and poor meibomian gland expressibility exclusion criteria: * eyelid structure abnormal(entropion , ectropion); * having received any other treatment for mgd within three months * history of ocular surgery * contact lens use * ocular infection * any type of corneal scarring

Keywords: thermal massage corneal aberrations physical therapy
primary pigmented nodular adrenocortical disease (ppnad) and the carney complex (cnc)

Conditions: Primary; Complex; Pigmented Nodular Adrenocortical Disease, Primary, 1; Periorificial Lentiginosis; Cardiac Myxoma

Summary: cohort cnc-ppnad will be investigated with clinical, genetic, biological and imaging work-up every year during 3 years. cohort l-mc will be investigated clinically at inclusion and a perkar1a genotype will be performed.

the primary aim is to assess the clinical manifestations of the carney complex (cnc) and/or the primary pigmented nodular adrenocortical disease (ppnad) in patients with cnc, isolated ppnad or carriers of prkar1a and ppnad1 (pde11a4) germline mutation (cohort cnc-ppnad). in this cohort genotype/phenotype correlation will be studied. a second aim is to determine the frequency of prkar1a germline mutation in patients with isolated cardiac myxoma or isolated lentiginosis (cohort l-mc).

Eligibility criteria:
inclusion criteria: cnc group : * patient with the carney complex (cnc) or the primary pigmented nodular adrenocortical disease (ppnad) or a germinal mutation of the gene of carney complex or ppnad. * no age criteria * inform consent of the patient or the parental authority collected * realization of a preliminary medical examination * affiliated with a social security system ( profit or having right) mc-l group : * patient with periorificial lentiginosis or cardiac myxoma * or previous history of periorificial lentiginosis or cardiac myxoma * age \> or = 18 years old * realization of a preliminary medical examination * affiliated with a social security system ( profit or having right) exclusion criteria : cnc group and mc-l group: * refusal or incapacity to take part in the study

Keywords: endocrinology, carney complex, primary pigmented nodular adrenocortical disease (ppnad), prkar1a
share model communication course and do-not-resuscitate signing

Conditions: Trauma Injury

Summary: this study aimed to investigate the effect of attending a share model communication course by emergency physicians on patient notification and signing of do-not-resuscitate (dnr) orders for critical patients in the emergency room.

an observation form designed based on the share model was completed by two observers who noted the communication process between physicians and patients and family members during patient notification and signing a dnr order. to assess the influence of physicians attending a share model course on the signing of dnr orders, a propensity score-matched population was created to reduce the potential selection bias of patients and family members.

Eligibility criteria:
inclusion criteria: * patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a "do not resuscitate" order. * patients who was not register with "do- not- resuscitate" on their health insurance card. exclusion criteria: * trauma patients. * suicide patients. * patients of age less than 20.
negative pressure wound therapy for surgical wounds of the foot and ankle

Conditions: Negative Pressure Wound Therapy; Vacuum Therapy; Closed Incisions

Summary: prophylactic use of negative pressure wound therapy (npwt) on surgical wounds following lower extremity orthopedic trauma to prevent infectious complications.


Eligibility criteria:
inclusion criteria: * patients ≥18 and ≤ 80 years * orthopedic (trauma) surgery to the foot and/or ankle * incision \>3 cm exclusion criteria: * open fractures * antibiotic treatment at the time of the operation for a concomitant disease or infection * insufficient comprehension of the dutch language * patients with immune-deficiencies * inability to address negative pressure wound therapy device * active infection

Keywords: npwt
promoting healthy families: a canadian evaluation

Conditions: Child Behavior Problem; Parenting

Summary: interventions that promote safe, stable, and nurturing relationships between caregivers and children are key to improving healthy family relationships, reducing child socioemotional and behaviour problems, and preventing child maltreatment. although a broad range of parenting programs are currently implemented in communities across ontario, most programs are inadequately evaluated, or else not evaluated at all. using a three-armed randomized controlled trial, the aim of the current study is to evaluate the effectiveness of two parenting programs, the triple p - positive parenting program (group - level 4) and the circle of security parenting program (group) compared to treatment as usual in ontario, canada.

the overall goal of the evaluation is to provide robust evidence about the implementation and effectiveness of two parenting programs, the triple p and circle of security parenting (cosp), in the province of ontario, on parenting practices and functioning, and child emotional behaviour problems outcomes, and secondary outcomes including selected child maltreatment-related outcomes. these objectives will be achieved in two phases. the investigators will conduct a multi-site, three-arm randomized controlled trial of 600 participating caregivers and their children to compare triple p (level 4 group) and cosp to treatment as usual (tau) with respect to improving positive practices and child outcomes. participants will be randomly assigned to one of the three conditions using stratified (by site) block randomization. all participants will undergo screening and a baseline assessment before randomization. once randomized, the triple p and cosp caregivers will receive 8-week session. the tau group will receive a different program, or short therapy sessions depending on the organization. caregivers will complete follow-up assessments at post-treatment, 6- and 12-months.

Eligibility criteria:
inclusion criteria: caregivers of children are eligible for inclusion if: * custodial caregiver of child is aged 2 to 6 years at time of screening. * families with sufficient knowledge of english needed for assessment measures. * caregivers capable of giving informed, written consent. * definition of 'at-risk' as measured by one of the following criteria as outlined below: * elevated child emotional behavioural problems as indexed by above- population mean total scores on the strengths and difficulties questionnaire (sdq); or * one of the following family or contextual risk factor * parental challenge - parental mental health problems, as indexed by score on k6 distress scale ≥ 13; adolescent parent status (less than 20 years of age); single parent status; or sociodemographic risk factor - parent with less than grade 12 education; parent on social assistance; * expressed difficulties with parenting: do you often feel like your child is difficult to take care of? exclusion criteria: • children with suspected severe to profound developmental delay.

Keywords: child behavior problem, parenting, parental capacity
tnf in melanoma patients treated with immunotherapy

Conditions: Melanoma

Summary: this trial is a translational proof-of-concept, open-label, prospective cohort study of 60 patients aiming to identify the clinical markers and/or biomarkers associated with therapeutic response to immune checkpoints inhibitors, in patients with advanced melanoma. the study will be conducted on a population of patients treated with ici in the context of routine care, separated in two subgroups: * subgroup 1: patients treated with anti-pd-1 alone (nivolumab or pembrolizumab) * subgroup 2: patients treated with the combined treatment anti-pd-1+anti-ctla-4 (nivolumab + ipilimumab) for each included patient, blood samples will be collected during baseline visit and during treatment period (at week 6 day 1 and week 12 day 1). if feasible, tumor biopsy (of primary tumor or metastasis) will be performed during baseline and on week 12 day 1 visit (predose). if tumor biopsy is not feasible, available archived tumor specimen (frozen or ffpe block) may be collected for the study. all included patients will be followed-up for tumor status and/or survival status every 3 months until a maximum duration of 1 year from the first study dose.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years at the time of study entry. 2. patient with histologically-proven metastatic and/or unresectable melanoma (stage iiic-iv, m1a-c as per ajcc 2009), including mucosal melanoma. 3. patient for which a treatment with immune checkpoint inhibitor (nivolumab alone, pembrolizumab alone or nivolumab + ipilimumab) has been decided. 4. subjects are included regardless of brafv600 mutation status. brafv600 mutation status must be documented. 5. patient must be naïve to immune checkpoint inhibitor treatment for locally advanced and/or metastatic disease (i.e., no prior treatment with ici and current treatment with ici not yet started). 6. ecog performance status 0-2. 7. life expectancy of at least 3 months. 8. patient able to participate and willing to give informed consent prior to performance of any study-related procedures and to comply with the study protocol. 9. patient affiliated to a social health insurance in france. exclusion criteria: 1. patient pregnant, or breast-feeding. 2. uveal melanoma. 3. any condition contraindicated with sampling procedures required by the protocol. 4. any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure. 5. any current severe or uncontrolled disease, including, but not limited to ongoing or active infection. 6. patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Keywords: melanoma tnf immune checkpoints tumor-infiltrating lymphocytes cytokines circulating leukocytes
home versus hospital based action observation therapy in diaplegic cerebral palsy

Conditions: Diplegic Cerebral Palsy

Summary: effects of home versus hospital based action observation therapy on balance, mobility and cognition in diaplegic cerebral palsy. it will be a rct we want to identify the effects of action observation therapy on patients coming to the hospital as compared to the patients at home. we will also identify the retaining effects of aot. our sample size will be 40 diplegic patients having no cognitive issues and able to walk with assistive device. we will exclude the patient who will suffer with severe comorbidities and visual impairment. we will randomly assign the patients into two groups a and b.a will receive action observation therapy three times a day along with stretching exercises .while group b we perform aot and stretching exercises at home with same frequency.


Eligibility criteria:
inclusion criteria: * participants falling in this category will be recruited into the study. * diagnosed diaplegic cp children between the age of 5 to 11 years. * without visual impairment and visual field defects. * able to follow the researcher's instruction. * gmfcs (gross motor function classification system) level i-iii. exclusion criteria: * participants failing to fall in this category will be excluded of the study. * children with a modified ashworth scale (mas) of 3 or more * unable to walk * children with severe co-morbidities. (2)
nutrients-fortified egg consumption on eczema condition in individuals with eczema

Conditions: Eczema, Atopic; Inflammation; Skin; Eczema; Hypersensitivity

Summary: the study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in individuals with eczema. it is hypothesised that daily consumption of nutrients-fortified egg, which is rich in antioxidants, will improve eczema conditions in individuals with eczema as compared to consumption of regular eggs.

eczema refers to a group of conditions that induces inflammation of the skin. of which, atopic dermatitis is the most common type. eczema is common in children, and can continue to adulthood. eczema is a chronic condition with no known cure. anti-inflammatory agents have been shown to protect against atopic dermatitis. vitamin d, e and polyunsaturated fatty acids are known to confer excellent anti-inflammatory benefits. this is a double-blinded, randomized, parallel study and all subjects will complete a 12-week study period. the study was designed based on previous research which reported that omega-3 supplementation significantly decreased blood ige concentration (-29.0 ± 11.1, mean ± sd) compared to placebo supplementation (-7.7 ± 14.6, mean ± sd).

Eligibility criteria:
inclusion criteria: 1. english-literate and able to give informed consent in english 2. male and female subjects, aged between 21 and 59 inclusive 3. healthy individuals with no comorbidities or on regular medication 4. bmi between 18.5-25 kg/m2 5. mild to moderate severity of eczema, which will also be determined using our questionnaires during screening visit exclusion criteria: 1. significant change in body weight (3 kg or more) in the past 3 months 2. significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week 3. known food allergy to eggs 4. taking dietary supplements which may impact the study results 5. had been diagnosed or with a history of gastrointestinal disorders e.g. irritable bowel syndrome, constipation, diverticulitis 6. current smokers 7. consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider or 45ml of distilled spirit 8. taking lipid-lowering and blood pressure controlling medications less than 3 years 9. pregnant or lactating women, or planning to conceive in the next 6 months 10. unwilling to stop the medication of eczema during the study, either topical creams or oral medications 11. hierarchical link (professional and familial ties) with the research team members 12. participating in another clinical study 13. having blindness in one eye or more, previously diagnosed eye diseases, or have had eye surgery 14. low quality macular pigment optical density results, determined during screening visit

Keywords: egg vitamin d vitamin e antioxidant eczema omega-3 long chain polyunsaturated fatty acids
atelectasis after pulmonary lobectomy: the effect of air during one-lung ventilation (olv) on postoperative atelectasis

Conditions: Pulmonary Atelectasis

Summary: patients scheduled for lung lobe resection using video assisted thoracic surgery will be randomly assigned to be ventilated with either only oxygen or a mixture of air and oxygen. the primary purpose of this study is to determine if the incidence of postoperative collapse (in the non-surgical lung) is decreased when using a mixture of air and oxygen compared to using only oxygen (which is our control measurement) during one-lung ventilation.

one of the concerns with all thoracic procedures employing one lung ventilation (olv) is intra-operative hypoxia due to the large shunt that develops when only one lung is being ventilated. ventilation with a higher fraction of inspired oxygen (fio2) is one of the commonly chosen strategies for the treatment of hypoxemia during (olv) for thoracic surgery. using an fio2 of 1.0 at all times during (olv), however, may increase the risk of absorption atelectasis intra and postoperatively which itself leads to persistent hypoxia and potentially pneumonia. the aim of this study is therefore to determine the impact of adding air to the inspired fraction of oxygen during (olv) primarily on the incidence of postoperative atelectasis of the nonsurgical lung after lung resection using video assisted thoracic surgery and secondarily on intraoperative and postoperative oxygenation.

Eligibility criteria:
inclusion criteria: * age 18 years or older * competent to give consent to enroll in study * booked for open thoracotomy procedure for lobectomy * american society of anesthesiologists comorbidity score 1-4 exclusion criteria: * unable or unwilling to give consent * pregnant women * inability to insert an arterial line * severe copd (fev1 \< .7% predicted, or fev1/fvc \< 0.70) * presence of other significant pulmonary impairment (pao2 on room air 50 mmhg, paco2 \> 50 mmhg or known pulmonary htn mean pap \> 25 mmhg) * presence of significant cardiovascular disease (+mibi that is non-revascularized, ccs ≥ 3 angina, nyha ≥ 3 chf, ef (by angiography or echocardiogram \< 40%) * chronic renal failure (serum cr \> 200) * altered liver function

Keywords: one lung ventilation atelectasis oxygenation
fih study of nrtx-1001 neural cell therapy in drug-resistant unilateral mesial temporal lobe epilepsy

Conditions: Mesial Temporal Lobe Epilepsy

Summary: this clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (nrtx-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (mtle), with or without mesial temporal sclerosis (mts), is safe (frequency of adverse events) and effective (seizure frequency). nrtx-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (gaba).

subjects will undergo a single ct or mri-guided intracerebral administration of human interneurons that secrete the inhibitory neurotransmitter, gamma-aminobutyric acid (gaba), into the temporal lobe region of the brain where the seizures are thought to arise. nrtx-1001 is intended to suppress the onset and spread of seizures. safety, tolerability, and effects on reducing seizure frequency and epilepsy disease symptoms will be assessed at quarterly intervals for 2 years after the administration of nrtx-1001. after the two-year period, subjects will be followed with quarterly phone calls and annual visits in years 3 through 5, and then annual visits in years 6 through 15. subjects will be placed on an immunosuppressant medication regimen for a duration of one year to partially suppress the subjects' immune system to promote the intended long-term persistence of nrtx-1001. this immunosuppressant medication is intended to be discontinued after the first year; however, the nrtx-1001 cells are intended to persist long-term.

Eligibility criteria:
key inclusion criteria: 1. male or female, age ≥18 to 75 2. focal seizures, clinically defined as unilateral mtle 3. has failed to achieve seizure control despite adequate trials of at least 2 asds at appropriate doses 4. currently on stable doses (at least 1 month) of approved asds 5. single seizure focus confirmed within one hippocampus 6. seizure frequency averages ≥4 per 28-day period, including at least 2 clinical focal seizures per 28-day period with objective manifestations or more severe types, over the 6 months prior to the screening visit. 7. considered (by investigator) to be a candidate for temporal lobectomy (tl) or laser interstitial thermal therapy (litt) following evaluation at a qualified epilepsy surgery program (national association of epilepsy centers \[naec\] level 4). key exclusion criteria: 1. epilepsy due to other and/or progressive neurologic disease 2. evidence of seizure focus outside of the hippocampus or evidence of seizures of non- focal origin. 3. significant other medical conditions which would impair safe participation 4. history of status epilepticus in the year prior to screening. a history of cluster seizures is permitted. 5. primary or secondary immunodeficiency 6. suicide attempts in the past year 7. severe psychiatric disorders 8. prior lobectomy or litt procedure 9. mri indicating potential malignant lesion 10. pregnancy, or currently breastfeeding.

Keywords: epilepsy mtle seizure
effect of psychological intervention on drop-out rates in ivf

Conditions: Infertility

Summary: the most common reason why insured in vitro fertilization (ivf) patients drop out of treatment is the distress caused by the treatment. the objective of this study is to determine the efficacy of a combined cognitive coping and relaxation intervention (ccri) in reducing drop out behavior in ivf patients.

intervention participants will be given a packet containing the ccri, which consists of two intervention components tailored to the stimulation phase and waiting phases of ivf. the cognitive component of the ccri is the prci intervention (boivin \& lancastle, 2008) tailored to the stimulation/waiting phases of an ivf cycle. the prci intervention consists of a series of ten statements that facilitate the use of cognitive reappraisal coping, a form of coping that helps people think more about the positive aspects of a difficult situation and dwell less on problems or uncertainties of the future. the relaxation components of the ccri consists of techniques that have been used for two decades in the mind/body infertility program as well as in randomized controlled research trials. for the stimulation phase, participants will receive instructions on how to do "mini relaxation" techniques which are specifically designed to reduce anxiety in the moment, for example feelings of tension, worry, and nervousness that might occur prior to and during stimulation phase procedures (e.g. injections, blood tests, and ultrasounds). for the waiting phase the relaxation intervention will include a relaxation cd. the cd contains narrated instruction on how to elicit the relaxation response through several techniques this is a randomized, controlled prospective study conducted at a private academically-affiliated infertility clinic and includes women ages 44 and below scheduled to undergo their first ivf cycle. subjects are randomized to a ccri or a control group. the primary outcome measure is dropout rates.

Eligibility criteria:
inclusion criteria: * first fresh ivf cycle * using own eggs * able to read, understand, and sign the informed consent in english * must have insurance coverage for ivf cycle exclusion criteria: * \>1 previous ivf cycle * donor egg cycle

Keywords: ivf drop out